Literature DB >> 25556921

Comparison of immunohistochemistry and DNA sequencing for the detection of IDH1 mutations in gliomas.

Yingjie Zou1, Harrison Xiao Bai1, Zhili Wang1, Li Yang1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25556921      PMCID： PMC4483104          DOI： 10.1093/neuonc/nou351

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  11 in total

Review 1.  IDH testing in diagnostic neuropathology: review and practical guideline article invited by the Euro-CNS research committee.

Authors:  M Preusser; D Capper; C Hartmann
Journal:  Clin Neuropathol       Date:  2011 Sep-Oct       Impact factor: 1.368

2.  Comparison of immunohistochemistry, DNA sequencing and allele-specific PCR for the detection of IDH1 mutations in gliomas.

Authors:  Delphine Loussouarn; Anne-Gaëlle Le Loupp; Jean-Sébastien Frenel; François Leclair; Andreas Von Deimling; Maud Aumont; Stéphane Martin; Mario Campone; Marc G Denis
Journal:  Int J Oncol       Date:  2012-03-16       Impact factor: 5.650

3.  Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing.

Authors:  Shingo Takano; Wei Tian; Masahide Matsuda; Tetsuya Yamamoto; Eiichi Ishikawa; Mika Kato Kaneko; Kentaro Yamazaki; Yukinari Kato; Akira Matsumura
Journal:  Brain Tumor Pathol       Date:  2011-02-23       Impact factor: 3.298

4.  Value and limitations of immunohistochemistry and gene sequencing for detection of the IDH1-R132H mutation in diffuse glioma biopsy specimens.

Authors:  Matthias Preusser; Adelheid Wöhrer; Susanne Stary; Romana Höftberger; Berthold Streubel; Johannes A Hainfellner
Journal:  J Neuropathol Exp Neurol       Date:  2011-08       Impact factor: 3.685

5.  Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors.

Authors:  David Capper; Susanne Weissert; Jörg Balss; Antje Habel; Jochen Meyer; Diana Jäger; Ulrike Ackermann; Claudia Tessmer; Andrey Korshunov; Hanswalter Zentgraf; Christian Hartmann; Andreas von Deimling
Journal:  Brain Pathol       Date:  2009-10-27       Impact factor: 6.508

6.  Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.

Authors:  Shipra Agarwal; Mehar Chand Sharma; Prerana Jha; Pankaj Pathak; Vaishali Suri; Chitra Sarkar; Kunzang Chosdol; Ashish Suri; Shashank Sharad Kale; Ashok Kumar Mahapatra; Pankaj Jha
Journal:  Neuro Oncol       Date:  2013-03-13       Impact factor: 12.300

Review 7.  Isocitrate dehydrogenase mutations in diffuse gliomas: clinical and aetiological implications.

Authors:  R Gupta; R Webb-Myers; S Flanagan; M E Buckland
Journal:  J Clin Pathol       Date:  2011-07-12       Impact factor: 4.463

8.  Predicting the likelihood of an isocitrate dehydrogenase 1 or 2 mutation in diagnoses of infiltrative glioma.

Authors:  Li Chen; Zoya Voronovich; Kenneth Clark; Isaac Hands; Jonathan Mannas; Meggen Walsh; Marina N Nikiforova; Eric B Durbin; Heidi Weiss; Craig Horbinski
Journal:  Neuro Oncol       Date:  2014-05-23       Impact factor: 13.029

9.  IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors.

Authors:  Marta Mellai; Angela Piazzi; Valentina Caldera; Oriana Monzeglio; Paola Cassoni; Guido Valente; Davide Schiffer
Journal:  J Neurooncol       Date:  2011-06-04       Impact factor: 4.506

10.  A new sensitive PCR assay for one-step detection of 12 IDH1/2 mutations in glioma.

Authors:  Aurélie Catteau; Hélène Girardi; Florence Monville; Cécile Poggionovo; Sabrina Carpentier; Véronique Frayssinet; Jesse Voss; Robert Jenkins; Blandine Boisselier; Karima Mokhtari; Marc Sanson; Hélène Peyro-Saint-Paul; Caterina Giannini
Journal:  Acta Neuropathol Commun       Date:  2014-06-02       Impact factor: 7.578
View more
  6 in total

1.  Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma.

Authors:  Jacob J Mandel; David Cachia; Diane Liu; Charmaine Wilson; Ken Aldape; Greg Fuller; John F de Groot
Journal:  J Neurooncol       Date:  2016-06-07       Impact factor: 4.130

2.  Updates in prognostic markers for gliomas.

Authors:  Elisa Aquilanti; Julie Miller; Sandro Santagata; Daniel P Cahill; Priscilla K Brastianos
Journal:  Neuro Oncol       Date:  2018-11-09       Impact factor: 12.300

3.  Clinical application of a highly sensitive digital PCR assay to detect a small fraction of IDH1 R132H-mutant alleles in diffuse gliomas.

Authors:  Kaishi Satomi; Akihiko Yoshida; Yuko Matsushita; Hirokazu Sugino; Kenji Fujimoto; Mai Honda-Kitahara; Masamichi Takahashi; Makoto Ohno; Yasuji Miyakita; Yoshitaka Narita; Yasushi Yatabe; Junji Shibahara; Koichi Ichimura
Journal:  Brain Tumor Pathol       Date:  2022-07-29       Impact factor: 3.154

4.  IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer.

Authors:  Jiang-Jiang Li; Ruilei Li; Wenxiang Wang; Baihua Zhang; Xin Song; Chunfang Zhang; Yang Gao; Qianjin Liao; Ya He; Shuo You; Zheqiong Tan; Xiangjian Luo; Yueshuo Li; Min Tang; Xinxian Weng; Wei Yi; Shifang Peng; Shaohui Liu; Ying Tan; Ann M Bode; Ya Cao
Journal:  Mol Oncol       Date:  2018-03-25       Impact factor: 7.449

5.  RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.

Authors:  Sean Chun-Chang Chen; Chung-Ming Lo; Shih-Hua Wang; Emily Chia-Yu Su
Journal:  BMC Bioinformatics       Date:  2019-12-24       Impact factor: 3.169

6.  Comparison of Polymerase Chain Reaction-Restriction Fragment Length Polymorphism, Immunohistochemistry, and DNA Sequencing for the Detection of IDH1 Mutations in Gliomas.

Authors:  Rusdy Ghazali Malueka; Emilia Theresia; Fitria Fitria; Ibnu Widya Argo; Aditya Dwi Donurizki; Sabillal Shaleh; Meutia Rizki Innayah; Adiguno Suryo Wicaksono; Kusumo Dananjoyo; Ahmad Asmedi; Rachmat Andi Hartanto; Ery Kus Dwianingsih
Journal:  Asian Pac J Cancer Prev       Date:  2020-11-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.